Index

Note: Page numbers of article titles are in **boldface** type.

A
ACE inhibitors. See Angiotensin-converting enzyme (ACE) inhibitors

Acid–base balance
  for CKD in cats, 1079–1080

Acute kidney injury (AKI)
  biomarkers for, 1002–1005
    in predicting early kidney injury, 1005–1008
  CKD vs., 998–1001
  early recognition of
    biomarkers in, 1005–1006
  kidney disease and nexus of, **961–993**
    slow
      progressive CKD as, **995–1013**
    UTI and
      biomarkers in predicting, 1006–1007

Acute rejection
  following kidney transplantation for CKD in animals, 1209–1211

Age
  as factor in CKD in cats, 1016–1018

AKI. See Acute kidney injury (AKI)

Aldosterone breakthrough
  in proteinuria management in dogs and cats with CKD, 1123

Aldosterone receptor antagonists
  in proteinuria management in dogs and cats with CKD, 1124

Anemia
  in CKD, **1168–1170**
    causes of, 1168
    epidemiology of, 1168
    evaluation of, 1168
    management of, 1169–1170

Anesthesia/anesthetics
  for kidney transplantation for CKD in animals, 1200–1202

Angiotensin-converting enzyme (ACE) inhibitors
  with ARBs
    in proteinuria management in dogs and cats with CKD, 1123
    in proteinuria management in dogs and cats with CKD, 1120–1123

Angiotensin receptor blockers (ARBs)
  with ACE inhibitors
    in proteinuria management in dogs and cats with CKD, 1123
    in proteinuria management in dogs and cats with CKD, 1121–1123

ARBs. See Angiotensin receptor blockers (ARBs)
B

Bartonellosis
  CKD in cats associated with, 1022

Bending tests
  in bone quality assessment, 1153–1154

Biomarker(s)
  for AKI, 1002–1005
    in predicting early kidney injury, 1005–1008
  defined, 962–963
  in kidney disease, 961–993
    in kidney function, 966
      criteria for, 945–946, 968
      discovery of, 965–966
      SDMA, 968–971
      specificity of, 971–975
  in predicting AKI
    in acute and chronic cardiorenal syndrome, 1008
    in UTI, 1006–1007

BMD. See Bone mineral density (BMD)

Body condition
  in cats with CKD, 1080–1082

Bone(s)
  cancellous
    properties of, 1158–1159
  quality of
    assessment of, 1153–1154

Bone mineral density (BMD)
  in bone quality assessment, 1153

C

Calcimimetics
  in CKD-MBD management, 1144

Calcium oxalate urolithiasis
  following kidney transplantation for CKD in animals, 1211

Calorie requirements
  for cats with CKD, 1102–1103

Cancellous bone
  properties of, 1158–1159

Cardiorenal syndrome
  AKI in
    biomarkers in predicting, 1008
  CKD in cats associated with, 1019–1020

Cat(s)
  CKD in
    age as factor in, 1016–1018
    causes of, 1016–1019
    concurrent disease states and, 1019–1022
      cardiorenal syndrome, 1019–1020
      diabetes mellitus, 1020
hyperthyroidism, 1020–1021
infectious diseases, 1021–1022
upper and lower urinary tract stone disease, 1021
demographic, environmental, and individual factors in, 1018–1019
dietary management for
acid–base balance in, 1079–1080
calorie requirements in, 1102–1103
decision process for feeding in, 1059–1061
energy intake, body weight loss, and body condition with, 1080–1082
fatty acids in, 1077–1078
future directions in, 1083–1085
goals in, 1067–1069
higher-protein diets in, 1058–1059
nutrients in, 1083
nutrition in, 1100
phosphorus in, 1075–1076
potassium in, 1078–1079
protein in, 1069–1075
sodium in, 1076–1077
water in, 1082–1083
food and water intake effects of, 1049–1050
malnutrition and, 1100–1102
management of
dietary (See Cat(s), CKD in, dietary management for)
feeding tubes in, 1099–1114 (See also Feeding tubes, in feline CKD management)
pathogenesis of
fibrosis in, 1026–1027
hemodynamic adaptations in, 1027–1028
hyperphosphatemia in, 1033–1034
hypoxia in, 1034–1035
oxidative stress in, 1035–1037
proteinuria in, 1032–1033
RAAS in, 1028–1031
renal inflammation in, 1022–1026
systemic hypertension in, 1031–1032
pathophysiology of, 1067–1069
progressive
maladaptive repair in, 1027
pathogenesis of, 1015–1048
protein for
differing viewpoints on, 1095–1098
proteinuria in
management of, 1115–1130 (See also Proteinuria, in dogs and cats with CKD, management of)
renal diets for, 1049–1065 (See also Renal diets, for cats with CKD)
water in, 1082–1083
reference interval development for, 950
SDMA as renal biomarker in, 969–971
SDMA correlation with GFR in, 947
SDMA level increases earlier than creatinine in, 950–951
secondary renal osteopathy in, 1151–1162
Chronic kidney disease (CKD)
AKI vs., 998–1001
in cats (See Cat(s), CKD in)
clinical manifestations of
   medical management of, 1163–1181
      anemia, 1168–1170
      constipation, 1174–1177
      hypertension, 1163–1166
      hypokalemia, 1166–1168
      with quality of life, 1177
      uremic dysrexia, nausea, and vomiting, 1170–1174
described, 1015–1016
introduction, 1193
IRIS guidelines for, 952–953
kidney disease and nexus of, 961–993
kidney transplantation for, 1193–1218 (See also Kidney transplantation, for CKD in animals)
management of
   early nutritional intervention in, 975
new look at, 1008–1011
prognostic indicator of
   proteinuria, 1116
progressive
   identification of, 1001–1002
   pathogenesis of
      in cats, 1015–1048 (See also Cat(s), CKD in)
      as slow AKI, 995–1013
renal osteodystrophy in, 1155–1158
renal secondary hyperparathyroidism in
   prevalence of, 1152
in small animals
diagnosing and staging of
   SDMA in, 941–960 (See also Symmetric dimethylarginine (SDMA), in diagnosis and staging of CKD in small animals)
Chronic kidney disease (CKD)-mineral and bone disorder (CKD-MBD), 1131–1149
described, 1131
renal osteodystrophy, 1134
renal secondary hyperparathyroidism, 1131–1134
treatment of, 1135–1141
   calcimimetics in, 1144
   controlling serum parathyroid hormone concentration in, 1141–1144
   dietary therapy in, 1137
   hemodialysis in, 1144
   for hyperphosphatemic, hypercalcemic patients, 1141
   for hyperphosphatemic, hypocalcemic patients, 1138–1139
   for hyperphosphatemic, normocalcemic patients, 1139–1141
   phosphate binders in, 1137–1138
   vitamin D analogues in, 1143–1144
update on, 1131–1149
vessel and tissue mineralization, 1135
CKD. See Chronic kidney disease (CKD)
CKD-MBD. See Chronic kidney disease (CKD)—mineral and bone disorder (CKD-MBD)

Clusterin
  urinary
    kidney-specific, 975–978

Constipation
  in CKD, 1174–1177
    causes of, 1174
    epidemiology of, 1174
    evaluation of, 1174–1175
    management of, 1175–1177

Cortical bone
  in renal osteodystrophy in CKD, 1156–1158

Creatinine
  as kidney function biomarker
    false responses related to, 963–965
    SDMA level increases earlier than
      in dogs and cats, 950–951

Cystatin B
  urinary and serum, 978–981

D

Diabetes mellitus
  CKD in cats associated with, 1020
    following kidney transplantation for CKD in animals, 1213

Diet(s)
  for CKD in cats
    renal diets, 1049–1065 (See also Renal diets, for cats with CKD)
    in CKD-MBD management, 1137
    in proteinuria management in dogs and cats with CKD, 1126

Dog(s)
  CKD in
    proteinuria in
      management of, 1115–1130 (See also Proteinuria, in dogs and cats with CKD, management of)
      reference interval development for, 947–949
      SDMA as renal biomarker in, 969–971
      SDMA level increases earlier than creatinine in, 950–951
      secondary renal osteopathy in, 1151–1162
      XLHN in
        SDMA correlation with GFR, 946–947

Drug therapy monitoring
  in proteinuria management in dogs and cats with CKD, 1124

E

Energy intake
  in cats with CKD, 1080–1082

Esophagostomy tube
  in feline CKD management, 1108
    maintenance of, 1108–1109
Fatty acids
for CKD in cats, 1077–1078

Feeding tubes
in feline CKD management, 1099–1114
  assisted enteral feeding, 1103–1105
  complications associated with, 1106–1108
  esophagostomy tube maintenance, 1108–1109
  introduction, 1099

Feline immunodeficiency virus
  CKD associated with, 1021

Food intake
  impaired kidney function effects on, 1049–1050

GFR. See Glomerular filtration rate (GFR)

Glomerular filtration rate (GFR)
in kidney function assessment
  challenges related to, 943–944
  SDMA correlation with, 968–969
  in diagnosis and staging of CKD in small animals, 946–947

Hemodialysis
  in CKD-MBD management, 1144

Hyperkalemia
  management of
    in proteinuria management in dogs and cats with CKD, 1125

Hyperparathyroidism
  renal secondary, 1131–1134

Hyperphosphatemia
  CKD in cats related to, 1033–1034

Hypertension
  in CKD, 1163–1166
    causes of, 1163–1164
    epidemiology of, 1163–1164
    evaluation of, 1164–1165
    management of, 1165–1166
  management of
    in proteinuria management in dogs and cats with CKD, 1125–1126
    systemic
      CKD in cats related to, 1031–1032

Hyperthyroidism
  CKD in cats associated with, 1020–1021

Hypokalemia
  in CKD, 1166–1168
    causes of, 1166
    epidemiology of, 1166
evaluation of, 1166–1167
management of, 1167–1168

Hypoxia
CKD in cats related to, 1034–1035

I

IDEXX SDMA test
in diagnosis and staging of CKD in small animals, 953–955

Immunosuppressive agents
complications related to
following kidney transplantation for CKD in animals, 1212–1213
in preoperative kidney transplantation treatment, 1199–1200
in proteinuria management in dogs and cats with CKD, 1127–1128

Infection(s)
immunosuppressive agents–related
following kidney transplantation for CKD in animals, 1212–1213

Infectious disease(s)
CKD in cats associated with, 1021–1022

Inflammatory cells
progressive CKD in cats related to, 1025

Inosine
serum, 981–982

International Renal Interest Society (IRIS)
guidelines for CKD, 952–953
guidelines for dietary therapy for CKD in cats, 1055–1056

International Renal Interest Society (IRIS) Napa Meeting
on kidney disease in small animals, 996–997

IRIS. See International Renal Interest Society (IRIS)

K

Kidney(s)
inflammation of
fibrosis related to
in cats, 1022–1026

Kidney biomarker
criteria for better
in kidney function assessment, 945–946

Kidney disease
biomarkers in, 961–993 (See also Biomarker(s))
nexus of CKD and AKI and, 961–993
in small animals
IRIS Napa Meeting on, 996–997

Kidney function
assessment of
challenges in, 943–946
analytical variability of SCr measurement, 945
criteria for better kidney biomarker, 945–946
GFR, 943–944
poor sensitivity and specificity of SCr testing, 944–945
Kidney (continued)

impaired
  effect on food and water intake, 1049–1050

Kidney injury

  early

    AKI biomarkers in predicting, 1005–1008

Kidney transplantation

  for CKD in animals, 1193–1128
    anesthetic management in, 1200–1202
    candidate presentation for, 1194
    complications of, 1209–1214
    donor screening in, 1198–1199
    introduction, 1193
    long-term management following, 1209
    outcome following, 1214
    perioperative complications related to
      troubleshooting for, 1207–1208
    postoperative monitoring, 1207–1208
    preoperative treatment for, 1199–1200
    recipient evaluation for, 1194–1197
    surgical procedure, 1202–1206

L

Leptospirosis

  CKD in cats associated with, 1022

M

Malnutrition

  CKD and, 1100–1102

MBDs. See Mineral and bone disorders (MBDs)

Mesenchymal stem cell (MSC) therapy

  in preoperative kidney transplantation treatment, 1200

Methylarginine synthesis, 942–943

Mineral and bone disorders (MBDs)

  in CKD, 1131–1149 (See also Chronic kidney disease (CKD)–mineral and bone disorder
      (CKD-MBD))

Morbillivirus

  CKD in cats associated with, 1022

MSC therapy. See Mesenchymal stem cell (MSC) therapy

Muscle wasting

  renal diets for cats with CKD and, 1056–1058

Myelofibroblast(s)

  progressive CKD in cats related to, 1024–1025

N

Nausea and vomiting

  in CKD, 1170–1174

Neoplasia
following kidney transplantation for CKD in animals, 1213

Nephroureteral obstructions, 1183–1192
  diagnosis of, 1184–1185
  introduction, 1183
  management of, 1186–1191
    decision-making process in, 1185–1186
    ureteral bypass in, 1190–1191
    ureteral stenting in, 1186–1190

Neutrophil-associated lipocalin (NGAL), 983–985
NGAL. See Neutrophil-associated lipocalin (NGAL)

Nutrients
  for CKD in cats, 1083

Nutrition
  in CKD management, 975
    in cats, 1100

O

Osteodystrophy
  renal (See Renal osteodystrophy)

Oxidative stress
  CKD in cats related to, 1035–1037

P

Pericyte(s)
  progressive CKD in cats related to, 1025

Phosphate binders
  in CKD-MBD management, 1137–1138

Phosphorus
  for CKD in cats, 1075–1076

Porosity
  in bone quality assessment, 1153

Potassium
  for CKD in cats, 1078–1079

Protein
  for CKD in cats, 1069–1075
    differing viewpoints on, 1095–1098
    normal renal handling of, 1116–1117
    urine
      laboratory tests for, 1117

Protein diets
  for cats with CKD, 1058–1059

Protein restriction
  in renal diets for cats with CKD
    rationale for, 1052–1055

Proteinuria
  in dogs and cats with CKD, 1032–1033
    clinical assessment of, 1118–1119
    management of, 1115–1130
      diet in, 1126
Proteinuria (continued)
  hypertension management in, 1125–1126
  immunosuppressive agents in, 1127–1128
  inhibition of RAAS in, 1119–1125 (See also Renin-angiotensin-aldosterone system (RAAS), inhibition of, in proteinuria management in dogs and cats with CKD)
  renal biopsy in, 1126–1127
  as prognostic indicator in CKD, 1116

Pyelonephritis
  CKD in cats associated with, 1021

Q

Quality of life
  in CKD management, 1177

R

RAAS. See Renin-angiotensin-aldosterone system (RAAS)
Reference intervals
  for cats, 950
  for dogs, 947–949
Renal biomarkers. See Biomarker(s)
Renal biopsy
  in proteinuria management in dogs and cats with CKD, 1126–1127
Renal diets
  for cats with CKD, 1049–1065
    adequate food consumption in, 1061–1062
    argument against, 1067–1094
    decision process for, 1059–1061
    evidence supporting, 1051–1052
    future directions for, 1059
    introduction, 1050–1051
    IRIS guidelines for, 1055–1056
    muscle wasting and uremic environment related to, 1056–1058
    protein diets, 1058–1059
      differing viewpoints on, 1095–1098
    protein restriction in
      rationale for, 1052–1055
Renal function
  SDMA as marker for, 968
Renal osteodystrophy, 1134
  in CKD, 1155–1158
  described, 1152
  in humans
    dogs and cats as model for, 1159
Renal osteopathy
  secondary
    in companion animals, 1151–1162
Renal secondary hyperparathyroidism, 1131–1134, 1151–1152
  bone abnormalities associated with, 1152
in CKD
prevalence of, 1152
Renin-angiotensin-aldosterone system (RAAS)
in CKD in cats, 1028–1031
inhibition of
in proteinuria management in dogs and cats with CKD, 1119–1125
ACE inhibitors, 1120–1121
ACE inhibitors with ARBs, 1123
aldosterone breakthrough, 1123
aldosterone receptor antagonists, 1124
ARBs, 1121–1123
drug therapy monitoring, 1124
hyperkalemia management, 1125
therapeutic adjustments in, 1124–1125
Retroperitoneal fibrosis
following kidney transplantation for CKD in animals, 1211

S
SCr testing. See Serum creatinine (SCr) testing
SDMA. See Symmetric dimethylarginine (SDMA)
Serum creatinine (SCr) measurements
analytical variability of
in kidney function assessment, 945
Serum creatinine (SCr) testing
poor sensitivity and specificity of
in kidney function assessment, 944–945
Serum inosine, 981–982
Stress
oxidative
CKD in cats related to, 1035–1037
Symmetric dimethylarginine (SDMA)
biochemistry of, 942–943, 967–968
in diagnosis and staging of CKD in small animals, 941–960
correlation with GFR, 946–947
IDEXX SDMA test in, 953–955
increases earlier than creatinine, 950–951
introduction, 941–942
IRIS in, 952–953
patient data and impact on, 955–956
reference interval development, 947–950
specificity of, 951–952
discovery of, 942, 966–967
elimination of, 943
GFR correlation with, 946–947, 968–969
as renal biomarker
in cats and dogs, 968–971
specificity of, 971–975
Systemic hypertension
CKD in cats related to, 1031–1032
Transplantation

kidney

for CKD in animals, 1193–1128 (See also Kidney transplantation, for CKD in animals)

Tubular epithelial cells

progressive CKD in cats related to, 1026

U

Upper and lower urinary tract stone disease

CKD in cats associated with, 1021

Uremic dysrexia

in CKD, 1170–1174

Uremic environment

renal diets for cats with CKD and, 1056–1058

Ureteral bypass

in nephroureteral obstruction management, 1190–1191

Ureteral stenting

in nephroureteral obstruction management, 1186–1190

Urinary tract infection (UTI)

AKI in

biomarkers in predicting, 1006–1007

CKD in cats associated with, 1021

Urinary tract stone disease

upper and lower

CKD in cats associated with, 1021

Urine protein

laboratory tests for, 1117

UTI. See Urinary tract infection (UTI)

V

Vessel and tissue mineralization, 1135

Vitamin D analogues

in CKD-MBD management, 1143–1144

Vomiting

in CKD, 1170–1174

W

Water intake

for CKD in cats, 1082–1083

impaired kidney function effects on, 1049–1050

Weight loss

in cats with CKD, 1080–1082

X

XLHN. See X-linked hereditary nephropathy (XLHN)

X-linked hereditary nephropathy (XLHN)

in dogs

SDMA correlation with GFR in, 946–947